Iwai K, Tashima M, Itoh M, Okazaki T, Yamamoto K, Ohno H, Marusawa H, Ueda Y, Nakamura T, Chiba T, Uchiyama T
Department of Hematology and Oncology, Clinical Sciences for Pathological Organs, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Bone Marrow Transplant. 2000 Jan;25(1):105-8. doi: 10.1038/sj.bmt.1702093.
It is widely accepted that seroconversion of HBsAg to HBsAb indicates clearance of hepatitis B virus. We describe a 50-year-old man with chronic myelocytic leukemia who developed lethal hepatitis B 22 months after allo-BMT. He had been negative for HBsAg and positive for HBsAb before BMT. Hepatitis B virus latently existing in the liver cells before BMT proliferated during the immunosuppressed period causing fatal hepatitis. Recipients with positive HBsAb should be considered to have the potential for active hepatitis B to emerge after BMT. Bone Marrow Transplantation (2000) 25, 105-108.
乙肝表面抗原（HBsAg）血清学转换为乙肝表面抗体（HBsAb）表明乙肝病毒清除，这一观点已被广泛接受。我们描述了一名50岁的慢性粒细胞白血病男性患者，其在异基因骨髓移植（allo-BMT）后22个月发生了致命性乙型肝炎。他在骨髓移植前乙肝表面抗原为阴性，乙肝表面抗体为阳性。骨髓移植前潜伏在肝细胞中的乙肝病毒在免疫抑制期增殖，导致了致命性肝炎。乙肝表面抗体阳性的受者应被视为在骨髓移植后有发生活动性乙型肝炎的可能性。《骨髓移植》（2000年）第25卷，第105 - 108页 。
